Latest News for 06/2020
28 Apr 2020
Back in October 2013 Medicines for Malaria Venture (MMV) selected a compound designed and developed at the Drug Discovery Unit (DDU), University of Dundee to enter preclinical development. In June 2015, the discovery, properties and mode of action of the compound DDD107498 were published in the journal Nature.
11 Jul 2019
Researchers from the Drug Discovery Unit have been awarded the “Project of the Year 2018” from Medicines for Malaria Venture (MMV) for their discovery work on potential new drugs for malaria. The annual award goes to the scientific partners involved in that year’s most exciting project from the MMV portfolio. MMV is the world’s leading product development partnership (PDP) for discovering and developing new effective and affordable medicines to treat malaria.
12 Feb 2019
Researchers in the Wellcome Centre for Anti-Infectives Research (WCAIR) have been awarded £700,000 to investigate whether bacteria and other natural products found in the Amazon hold the key to developing new drugs for neglected tropical diseases. The team led by Professor Kevin Read will work with colleagues in Brazil to identify novel drug targets and develop new therapies for visceral leishmaniasis and Chagas’ disease.
25 Jul 2018
A new preclinical candidate drug with the potential to treat visceral leishmaniasis, one of the world’s major neglected diseases, has been discovered through a close collaboration between the University of Dundee, GSK and Wellcome.
17 Jan 2018
Kevin Read and Simon Arthur have been promoted to Personal Chair (Professor) as part of the 2017 Annual Review process for academic staff. Kevin Read will become Professor of Quantitative Pharmacology while Simon Arthur will be Professor of Immune Signalling. “I would like to congratulate both Kevin and Simon on their well-deserved promotions,” said Professor Julian Blow, Dean of Research in the School of Life Sciences. “Both have made significant contributions to their respective fields over a sustained period of time as well as contributing to teaching our undergraduates.”
19 Jun 2017
A new Centre for Excellence in New Psychoactive Substances (NPS) Research has been created at the University of Dundee to help tackle the emerging epidemic of highly addictive new drugs. The Centre forms the research arm of a wider initiative with the Scottish Police Authority Forensic Services and the Scottish Government, creating a Drugs and NPS forensic capability for Scotland.
04 Nov 2016
Scientists at the University of Dundee have identified a `molecular commando’ which can be stealthily deployed to activate a hypoxic response, a process which can help to fight a range of conditions including stroke, angina, colitis and brain injuries. A Dundee team led by Professor Alessio Ciulli have used pioneering techniques to develop a `small molecule’ chemical probe called VH298, which offers highly targeted access to the parts of the cell which regulate hypoxia, known as the hypoxic signalling pathway.
03 Nov 2016
A newly identified method of activating drugs to combat one of the world’s most destructive `neglected’ diseases could lead to better medicines according to new research led by the University of Dundee. Visceral leishmaniasis (VL) is a disease which blights the developing world with 200,000 to 400,000 new cases and an estimated 40,000 deaths annually, making it the second biggest parasitic killer after malaria. The vast majority of cases are seen in seven countries - India, Nepal, Bangladesh, Brazil, Ethiopia, South Sudan and Sudan.
30 Jun 2015
The Drug Discovery Unit at the University of Dundee has been awarded “Project of the Year, 2014” by the not-for-profit organisation, Medicines for Malaria Venture for their work on the new potential anti-malaria compound “DDD107498 – The Compound with Muscle”. The discovery of the compound was recently published in the journal Nature and has been selected as a preclinical candidate by MMV and recently partnered with the pharmaceutical company Merck Serono.
17 Jun 2015
The details of the discovery, properties and mechanism of action of a novel antimalarial compound, DDD107498, have been published in the journal Nature. DDD107498 has the potential to treat malaria patients in a single dose, including those with malaria parasites resistant to current medications, and help reduce the transmission of the parasite. The compound was identified through a collaboration between the University of Dundee’s Drug Discovery Unit (DDU) and Medicines for Malaria Venture (MMV).